Albany Molecular Resh Inc (NASDAQ:AMRI)

CAPS Rating: 2 out of 5

The Company is a global chemistry-based drug discovery and development company focused on identifying and developing novel biologically active small molecules with applications in the drug market.

Results 1 - 18 of 18

Recs

0
Member Avatar TerryHoodSr (54.30) Submitted: 7/29/2013 10:57:07 PM : Outperform Start Price: $10.45 AMRI Score: +48.11

growth

Recs

1
Member Avatar SamsaricSufferer (< 20) Submitted: 4/27/2013 9:35:49 PM : Outperform Start Price: $11.15 AMRI Score: +30.92

The turn around is officially complete.

Recs

0
Member Avatar just1man4picking (< 20) Submitted: 4/25/2013 11:11:42 AM : Outperform Start Price: $11.52 AMRI Score: +26.36

This is an outstanding company with outstanding opportunities...they know how to execute.

Recs

0
Member Avatar cecamado1 (99.98) Submitted: 8/29/2011 3:20:48 PM : Outperform Start Price: $3.53 AMRI Score: +315.69

Langer

Recs

0
Member Avatar bluetitan (< 20) Submitted: 12/28/2010 9:44:27 AM : Outperform Start Price: $5.68 AMRI Score: +143.50

My advisor brought this stock to my attention. Ever since the tech bubble burst back in 2000 this stock has been trading flat or trending down. It made a few attempts to rise but has given the impression that it can't go up. The recent quiet action along with quiet volume and shakeout from the $10 level is a great time to buy. I think this stock has a large rise in its future which could take years to develop. All I know is buy now when it has turned very quiet and has now been under accumulation for the better part of 10 years. Be patient and I believe you will be rewarded.

Recs

1
Member Avatar exemployee1 (< 20) Submitted: 4/11/2010 7:48:29 AM : Underperform Start Price: $8.53 AMRI Score: -38.24

This company is not at all well run. It does not take care of its employees. Instead, it uses them and throws them away resulting in excessive turn over. Communication within the company is highly controlled and honesty will result in retaliation. This is all easily verifiable. Ask any of the literally hundreds of people who no long work for them. This is a signal of institional sickness and the buck falls at the very top...but money keeps some people in control.

Recs

0
Member Avatar brianpivar (< 20) Submitted: 11/4/2009 8:15:24 PM : Underperform Start Price: $8.16 AMRI Score: -26.27

EPS 08: .62 p/e 13.1
EPS 09: .05 p/e 162.8
EPS 10: .13 p/e 62.62

Fundamentally speaking, this is a sell

Recs

0
Member Avatar dusand (59.09) Submitted: 9/18/2009 10:25:21 AM : Outperform Start Price: $8.29 AMRI Score: +25.54

Profitable pharmacy research and development company with good valuation ratios and low debt. Also, I feel the chart has already reached the bottom.

Recs

0
Member Avatar NWTOGME (< 20) Submitted: 10/4/2008 3:19:52 PM : Outperform Start Price: $14.21 AMRI Score: -62.52

L/R D/E ratio's look good.

Recs

0
Member Avatar equalfuture (< 20) Submitted: 4/10/2008 4:52:05 AM : Outperform Start Price: $11.74 AMRI Score: -2.01

BUYING AT 5 PER SHARE, stock is valued in my fair value estimates at 5.40 a share i expect movement at this price in late summer.

good company worth 5 or more a share.

Recs

0
Member Avatar samlove (67.14) Submitted: 1/2/2008 1:52:56 PM : Outperform Start Price: $13.70 AMRI Score: -13.72

On a strictly technical basis, my magic charts say this will outperform the S&P

Recs

0
Member Avatar NeroSagetrade (93.78) Submitted: 10/9/2007 11:05:33 PM : Outperform Start Price: $16.83 AMRI Score: -27.11

Albany Molecular Research is another case of the slow and steady turtle executing with a solid management team to deliver results. The past four quarters have shown rather large earnings beats and at 31 times earnings and with $3.14 per share in cash I think they can solidly deliver 15% stock price appreciation per annum. The price to book valuation is in-line if not just below the sector average and the long-term technicals show an ascending triangle that wants to break hgiher above $18. All signs pointing higher.

Nero

Sagetrade

Recs

0
Member Avatar xylitol02 (< 20) Submitted: 7/19/2007 5:37:06 AM : Outperform Start Price: $16.81 AMRI Score: -28.27

new

Recs

0
Member Avatar Brob84 (< 20) Submitted: 6/23/2007 1:22:57 PM : Outperform Start Price: $14.70 AMRI Score: -18.28

Growing by pharmaceutical development and licensing or partnership with large pharma corps.

Recs

0
Member Avatar traderz999 (< 20) Submitted: 6/17/2007 6:21:27 PM : Outperform Start Price: $15.06 AMRI Score: -18.29

sc score 10, good earning forecast

Recs

0
Member Avatar GaTeek (< 20) Submitted: 5/3/2007 6:57:10 PM : Outperform Start Price: $10.65 AMRI Score: +24.59

Lagging CRO sector, plus participation in near term drug discovery candidates

Recs

0
Member Avatar skc0001 (44.93) Submitted: 10/30/2006 3:11:34 AM : Outperform Start Price: $11.91 AMRI Score: -5.04

a VALUE PROPOSITION

Recs

0
Member Avatar edrc (87.12) Submitted: 10/24/2006 2:58:31 PM : Outperform Start Price: $11.38 AMRI Score: +0.93

Strong company, recent run up on no news suggest good news coming.

Results 1 - 18 of 18

Featured Broker Partners


Advertisement